Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease

Brain Research

Volumn 994, Issue 1, 2003, Pages 44-54

  Saydoff, Joel A ^a   Liu, Lian Sheng ^a   Garcia, Rolando A G ^a   Hu, Zhongyi ^a   Li, Donna ^b   Von Borstel, Reid W ^a  

^a Wellstat Therapeutics Corporation   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Huntington's; Mitochondria; Neurodegeneration; Neuroprotection; Pyrimidine; Uridine

Indexed keywords

3 NITROPROPIONIC ACID; PN 401; PRODRUG; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MEGADOSE; HUNTINGTON CHOREA; MALE; MORTALITY; MOTOR ACTIVITY; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; THALAMUS; WEIGHT REDUCTION;

EID: 0344875113     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.09.049     Document Type: Article

References (55)

1. Angermuller S., Loffler M. Localization of dihydroorotate oxidase in myocardium and kidney cortex of the rat. An electron microscopic study using the cerium technique. Histochem. Cell Biol. 103:1995;287-292.
2. Araujo D.M., Hilt D.C. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience. 82:1998;117-127.
3. Aussedat J. Effect of uridine supply on glycogen resynthesis after ischaemia in the isolated perfused rat heart. Cardiovasc. Res. 17:1983;145-151.
4. Beal M.F. Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. 7:1994;542-547.
5. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta. 1366:1998;211-223.
6. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. TINS. 23:2000;298-304.
7. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
8. Bennett M.C., Diamond D.M., Stryker S.L., Parks J.K., Parker W.D. Jr. Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 5:1992;93-101.
9. Borlongan C.V., Koutouzis T.K., Freeman T.B., Cahill D.W., Sanberg P.R. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motor symptoms of Huntington's disease. Brain Res. 697:1995;254-257.
10. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41:1997;646-653.
11. Browne S.E., Bowling A.C., Baik M.J., Gurney M., Brown R.H. Jr., Beal M.F. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J. Neurochem. 71:1998;281-287.
12. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 9:1999;147-163.
13. Cooper J.M., Schapira A.H. Mitochondrial dysfunction in neurodegeneration. J. Bioenerg. Biomembranes. 29:1997;175-183.
14. Cornford E.M., Oldendorf W.H. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta. 394:1975;211-219.
15. de Erausquin G.A., Manev H., Guidotti A., Costa E., Brooker G. Gangliosides normalize distorted single-cell intracellular free Ca2+ dynamics after toxic doses of glutamate in cerebellar granule cells. Proc. Natl. Acad. Sci. U. S. A. 87:1990;8017-8021.
16. Desjardins P., Frost E., Morais R. Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol. Cell. Biol. 5:1985;1163-1169.
17. Donohoe J.A., Rosenfeldt F.L., Munsch C.M., Williams J.F. The effect of orotic acid treatment on the energy and carbohydrate metabolism of the hypertrophying rat heart. Int. J. Biochem. 25:1993;163-182.
18. Ferrante R., Brouillet E., Palfi S., Kowall N., Hantraye P., Beal M. Mitochondrial dysfunction as a model for Huntington's disease using the electron transport chain inhibitor 3-nitropropionic acid. Beal M., Howell N., Bodis-Wollner I. Mitochondria and Free Radicals in Neurodegenerative Diseases. 1997;229-244 Wiley-Liss, New York.
19. Fix A.S., Ross J.F., Stitzel S.R., Switzer R.C. Integrated evaluation of central nervous system lesions: stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK-801-induced neuronal necrosis in the rat cerebral cortex. Toxicol. Pathol. 24:1996;291-304.
20. Gabrielson K.L., Hogue B.A., Bohr V.A., Cardounel A.J., Nakajima W., Kofler J., Zweier J.L., Rodriguez E.R., Martin L.J., de Souza-Pinto N.C., Bressler J. Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am. J. Pathol. 159:2001;1507-1520.
21. Geiger A., Yamasaki S. Cytidine and uridine requirement of the brain. J. Neurochem. 1:1956;93-100.
22. Hadjiconstantinou M., Neff N.H. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 51:1988;1190-1196.
23. Hidalgo M., Villalona-Calero M.A., Eckhardt S.G., Drengler R.L., Rodriguez G., Hammond L.A., Diab S.G., Weiss G., Garner A.M., Campbell E., Davidson K., Louie A., O'Neil J.D., von Borstel R., Von Hoff D.D., Rowinsky E.K. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J. Clin. Oncol. 18:2000;167-177.
24. Karle J.M., Anderson L.W., Cysyk R.L. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. J. Biol. Chem. 259:1984;67-72.
25. Keilbaugh S.A., Hobbs G.A., Simpson M.V. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Mol. Pharmacol. 44:1993;702-706.
26. Kelsen D.P., Martin D., O'Neil J., Schwartz G., Saltz L., Sung M.T., von Borstel R., Bertino J. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J. Clin. Oncol. 15:1997;1511-1517.
27. Kim G.W., Chan P.H. Oxidative stress and neuronal DNA fragmentation mediate age-dependent vulnerability to the mitochondrial toxin, 3-nitropropionic acid, in the mouse striatum. Neurobiol. Dis. 8:2001;114-126.
28. Kim G.W., Copin J.C., Kawase M., Chen S.F., Sato S., Gobbel G.T., Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20:2000;119-129.
29. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 246:1989;500-503.
30. Lin Z., Richards S., Rosenfeldt F., Pepe S. Uridine preserves ATP during hypoxic perfusion of the rat heart. Asia Pacific Heart. 6:1997;190-196.
31. Löffler M., Jockel J., Schuster G., Becker C. Dihydroorotat- ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol. Cell. Biochem. 174:1997;125-129.
32. Lombardi G., Zanoni R., Moroni F. Systemic treatments with GM1 ganglioside reduce quinolinic acid-induced striatal lesions in the rat. Eur. J. Pharmacol. 174:1989;123-125.
33. Lortet S., Aussedat J., Rossi A. Pyrimidine nucleotide synthesis from exogenous cytidine in the isolated rat heart. Basic Res. Cardiol. 81:1986;303-310.
34. Martin D.S., Stolfi R.L., Sawyer R.C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother. Pharmacol. 24:1989;9-14.
35. Mattson M.P., Pedersen W.A., Duan W., Culmsee C., Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12808-12812.
36. Miller P.J., Zaborszky L. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease. Exp. Neurol. 146:1997;212-229.
37. Morais R., Guertin D., Kornblatt J.A. On the contribution of the mitochondrial genome to the growth of Chinese hamster embryo cells in culture. Can. J. Biochem. 60:1982;290-294.
38. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
39. Parrou J.L., Francois J. A simplified procedure for a rapid and reliable assay of both glycogen and trehalose in whole yeast cells. Anal. Biochem. 248:1997;186-188.
40. Penney J., Young A. Huntington's disease. Jankovic J., Tolosa E. Parkinson's Disease and Movement Disorders. 1998;341-355 Williams and Wilkins, Baltimore.
41. Peters G.J., Schwartsmann G., Nadal J.C., Laurensse E.J., van Groeningen C.J., van der Vijgh W.J., Pinedo H.M. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res. 50:1990;4644-4649.
42. Schapira A.H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta. 1410:1999;159-170.
43. Schneider J.S., Kean A., DiStefano L. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J. Neurosci. Res. 42:1995;117-123.
44. Schulz J.B., Henshaw D.R., MacGarvey U., Beal M.F. Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochem. Int. 29:1996;167-171.
45. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174:1997;193-197.
46. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P. Jr., Davis R.E., Parker W.D. Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:1996;663-671.
47. Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett J.P. Jr., Davis R.E., Parker W.D. Jr. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 49:1997;918-925.
48. Switzer R.C. Strategies for assessing neurotoxicity. Neurosci. Biobehav. Rev. 15:1991;89-93.
49. Switzer R.C. Silver staining methods: their role in detecting neurotoxicity. Ann. N.Y. Acad. Sci. 679:1993;341-348.
50. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45:1999;25-32.
51. Vaillant F., Loveland B.E., Nagley P., Linnane A.W. Some biochemical properties of human lymphoblastoid Namalwa cells grown anaerobically. Biochem. Int. 23:1991;571-580.
52. Werner A., Siems W., Schmidt H., Rapoport I., Gerber G., Toguzov R.T., Tikhonov Y.V., Pimenov A.M. Determination of nucleotides, nucleosides and nucleobases in cells of different complexity by reversed-phase and ion-pair high-performance liquid chromatography. J. Chromatogr. 421:1987;257-265.
53. Yu R.K., Ariga T. Ganglioside analysis by high-performance thin-layer chromatography. Methods Enzymol. 312:2000;115-134.
54. Zaharevitz D.W., Anderson L.W., Malinowski N.M., Hyman R., Strong J.M., Cysyk R.L. Contribution of de-novo and salvage synthesis to the uracil nucleotide pool in mouse tissues and tumors in vivo. Eur. J. Biochem. 210:1992;293-296.
55. Zheng X., Shoffner J.M., Lott M.T., Voljavec A.S., Krawiecki N.S., Winn K., Wallace D.C. Evidence in a lethal infantile mitochondrial disease for a nuclear mutation affecting respiratory complexes I and IV. Neurology. 39:1989;1203-1209.